[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100380453":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":34,"centralContacts":39,"locations":48,"responsibleParty":65,"collaborators":67,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":79,"minAge":80,"maxAge":10,"enrollmentInfo":81,"targetDuration":10,"studyType":84,"phases":10,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":51,"whyStopped":10,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Insel Gruppe AG, University Hospital Bern","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence optimization (Healthy Control Group 1 (10 Persons))",null,"The MEGA-based editing sequences as well as the SLOW-EPSI sequence will be applied to this group using a 3T Prisma and a 7T Terra scanner. Data will be used for optimization of the pulse sequences.\n\nAim: find those sequence parameters to obtain best spectral quality data (SNR, spatial resolution versus measurement time).",[13],"Device: MR-scans using a 3T Prisma and a 7T Terra scanner (Siemens, Erlangen Germany)",{"label":15,"type":10,"description":16,"interventionNames":17},"Healthy Control Group 2 (15 Persons)","The best performing sequence which will be applied to this group using a 7T Terra scanner. Data will be used normative data for glutamate\u002Fglutamine and GABA levels in healthy controls.\n\nAim: normal reference data for future studies.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Patient Group 1: Comparison of 5 different spectral editing sequences (30 Patients)","Two editing pulse sequence types will be applied to this group at a 3T Prisma and a 7T Terra scanner. The sequences being compared are MEGA-semiLASER-SVS, MEGA-semiLASER based MRSI (on both 3T and 7T) and SLOW-EPSI (on 7T only).",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Patient Group 1: Comparison of 4 different CEST sequences (30 Patients)","Two different CEST sequence types will be applied to this group at a 3T Prisma and a 7T Terra scanner. The CEST performance will be compared between 3T and 7T, as well which of the two types in the best on each scanner.\n\nAim: which of the four sequence predicts the IDH-mutation status best.",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DEVICE","MR-scans using a 3T Prisma and a 7T Terra scanner (Siemens, Erlangen Germany)","The MR-scans performed at 3T and 7T are performed to evaluate whether high field MR-examinations bring an advantage to the patient in determining the IDH-status of the glioma. Two MRSI\u002FCEST sequences will be tested against each other.",[15,23,19,9],[33],"Examined are fast MRSI sequences and CEST sequences.",[35],{"name":36,"affiliation":37,"role":38},"Johannes Slotboom, PhD","University of Bern","STUDY_CHAIR",[40,44],{"name":36,"role":41,"phone":42,"phoneExt":10,"email":43},"CONTACT","+41316327469","johannes.slotboom@gmail.com",{"name":45,"role":41,"phone":46,"phoneExt":10,"email":47},"Marwan El-Koussy, MD","+41316320008","marwan.el-koussy@insel.ch",[49],{"facility":50,"status":51,"city":52,"state":10,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Institute for Diagnostic and Interventional Neuroradiology, University Hospital Bern","RECRUITING","Bern","3010","Switzerland","CH",{"type":57,"coordinates":58},"Point",[59,60],7.44744,46.94809,{"lat":60,"lon":59},[63],{"name":36,"role":41,"phone":42,"phoneExt":10,"email":64},"johannes.slotboom@insel.ch",{"type":66,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[68],{"name":69,"class":6},"Swiss National Science Foundation","100380453","metabolic-characterization-of-space-occupying-lesions-of-the-brain-100380453",false,"NCT04233788","Metabolic Characterization of Space Occupying Lesions of the Brain","Metabolic Characterization of Space Occupying Lesions of the Brain Using in Vivo MR- (Spectroscopic) Imaging at 3 Tesla and 7 Tesla","FASTMRSI","Inclusion Criteria:\n\n* Healthy people who are able to lie in the MR scanner for one hour;\n* Patients with suspected mass in the brain\n* Written informed consent\n\nExclusion Criteria:\n\n* Persons under the age of 18\n* Persons who are mentally unable to choose to participate\n* Pregnant women\n* Patients with oncological findings or neurodegenerative findings in the past\n* Wearing active implants (e.g. pacemakers and neurostimulators)\n* Emergency patients\n* Persons with tattoos on the head or neck area",true,"ALL","18 Years",{"count":82,"type":83},55,"ESTIMATED","OBSERVATIONAL","High field MR-technologies are expected to boost metabolic spectroscopic imaging (MRSI), but also CEST-MRI. This is due to the fact that increased SNR is available which can be used to increase the spatial resolution of all sequences, or reduction of measurement times. Recent findings has shown that MRSI can be used to evaluate the isocitrate dehydrogenase (IDH) status of gliomas, a brain tumor type which is most often diagnosed in humans. Patients with IDH-mutated gliomas have a much longer survival time that IDH-wildtype. In IDH-mutated gliomas the substance 2-hydroxy-glutarate (2HG) is found, whereas in IDH-wildtype gliomas it is not.\n\nThe underlying trial aims to measure 2HG directly with different MRSI sequences at 3 Tesla (3T) and 7 Tesla (7T) magnetic field strength. Apart from MRSI-techniques for IDH-typing it has been shown that CEST-imaging can also be performed to determine the IDH-status of gliomas.\n\nA total of 75 patients and 50 healthy controls will be examined in this study to evaluate the most accurate method for pre-operative IDH-status determination.",[87,88,89],"Brain Tumor","Glioma","IDH Mutation",[91,92,93,94,95,96],"Magnetic Resonance Spectroscopic Imaging (MRSI)","Chemical exchange saturation transfer imaging (CEST)","Pulse sequence development","Preoperative prediction of IDH-status","Quantitative MR(S)I","Signal processing","2024-11-20",{"date":99,"type":100},"2024-11-25","ACTUAL",{"date":102,"type":100},"2021-09-01",{"date":104,"type":83},"2025-12-31",{"name":5,"class":6},1]